BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NanoSight Limited Named in the Sunday Times Tech Track 100 UK Companies


9/24/2013 11:04:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Salisbury, UK, 24th September, 2013: NanoSight, world leaders in nanoparticle characterization, has been listed in the 2013 Sunday Times Tech Track 100 sponsored by Hiscox.

The thirteenth annual Tech Track 100 league table supplement was published in The Sunday Times on 15 September 2013, with title sponsor Hiscox. Tech Track ranks Britain's private tech (TMT) companies with the fastest-growing sales over the last three years, for companies with sales over £5m.

NanoSight was placed in 70th position in recognition of continued exponential growth reflected in their sales performance since 2006, when company sales of their unique Nanoparticle Tracking Analysis (NTA) technology took off. Speaking of this latest award for excellence, CEO Jeremy Warren says "On behalf of NanoSight's team, I am very pleased for the company to be recognized in this way; Tech Track recognition certainly validates our work. 2013 has seen us continue to grow sales on the back of new technology developments, such as the launch of our new NS300 system at Pittcon and more recently, the addition of dynamic light scattering, DLS, capability to the flagship NS500 system."

Founder and Chief Technical Officer, Bob Carr, is particularly excited by the recognition of the technology through the publication of nearly 1,000 peer-reviewed papers citing NTA. "I am very proud to see the work of our development team provide technology which is making a significant difference in nanotechnology, the life sciences in particular. We have seen tremendous advances in the study of exosomes where their use as biomarkers with potential for early stage diagnosis of various cancers. Our other areas in which we have seen growth include protein aggregation and the study of viruses and vaccines. Now we look to expanding into more areas as our technology is being used in more and more applications areas."

To find out about the business and to learn more about particle characterization using NanoSight's unique Nanoparticle Tracking Analysis solutions, visit www.nanosight.com and register to receive the next issue of NanoTrail, the company's electronic newsletter.

About NanoSight:

NanoSight delivers the world's most versatile and proven multi-parameter nanoparticle analysis in a single instrument.

NanoSight's "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements are similarly particle-specific. It is this particle-by-particle methodology that takes NTA beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.

This simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.

NanoSight has installed more than 600 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight's technology is validated by 900+ third party papers citing NanoSight results. NanoSight's leadership position in nanoparticle characterization is consolidated further with publication of an ASTM International standard, ASTM E2834, which describes the NTA methodology for detection and analysis of nanoparticles. For more information, visit www.nanosight.com.

For further information:

Please contact NanoSight direct or their marketing agency, Talking Science:

NanoSight Limited

Minton Park

London Road

Amesbury SP4 7RT UK

T +44(0)1980 676060

F +44(0)1980 624703

www.nanosight.com

sarah.newell@nanosight.com

Talking Science Limited

39 de Bohun Court

Saffron Walden

Essex CB10 2BA UK

T +44(0)1799 521881

M +44(0)7843 012997

www.talking-science.com

jezz@talking-science.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES